Randomized phase II study comparing neoadjuvant 5-fluorouracil/oxaliplatin/docetaxel versus docetaxel/oxaliplatin/S-1 for patients with type 4 or large type 3 gastric cancer

References

• Katanoda K , KamoK-I, SaikaKet al. Short-term projection of cancer incidence in Japan using an age-period interaction model with spline smoothing. Jpn J. Clin. Oncol.44(1), 36–41 (2014).
   PubMed Web of Science ®Google Scholar
• Japanese Gastric Cancer Association Registration Committee , MaruyamaK, KaminishiMet al.Gastric cancer treated in 1991 in Japan: data analysis of nationwide registry. Gastric Cancer9(2), 51–66 (2006).
   PubMedGoogle Scholar
• Cunningham D , AllumWH, StenningSPet al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med.355(1), 11–20 (2006).
   PubMed Web of Science ®Google Scholar
• Smalley SR , BenedettiJK, HallerDGet al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J. Clin. Oncol.30(19), 2327–2333 (2012).
   PubMed Web of Science ®Google Scholar
• Jung K , ParkMI, KimSE, ParkSJ. Borrmann type 4 advanced gastric cancer: focus on the development of scirrhous gastric cancer. Clin Endosc.49(4), 336–45 (2016).
   PubMedGoogle Scholar
• An JY , KangTH, ChoiMG, NohJH, SohnTS, KimS. Borrmann type IV: an independent prognostic factor for survival in gastric cancer. J. Gastrointest. Surg.12(8), 1364–1369 (2008).
   PubMed Web of Science ®Google Scholar
• Hirata Y , AgnesA, PrakashLR, MansfieldP, BadgwellBD, IkomaN. Borrmann type predicts response to preoperative therapy in advanced gastric cancer. J. Gastrointest. Cancer10.1007/s12029-022-00880-6 (2022) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Vivier-Chicoteau J , LambertJ, CoriatRet al. Development and internal validation of a diagnostic score for gastric linitis plastica. Gastric Cancer23(4), 639–647 (2020).
   PubMed Web of Science ®Google Scholar
• Nashimoto A , AkazawaK, IsobeYet al. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer16(1), 1–27 (2013).
   PubMed Web of Science ®Google Scholar
• Iwasaki Y , SasakoM, YamamotoSet al. Phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210): phase II study for gastric cancer. J. Surg. Oncol.107(7), 741–745 (2013).
   PubMed Web of Science ®Google Scholar
• Iwasaki Y , TerashimaM, MizusawaJet al. Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial. Gastric Cancer24(2), 492–502 (2021).
   PubMed Web of Science ®Google Scholar
• Kobayashi M , SakamotoJ, NamikawaTet al. Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients. World J. Gastroenterol.12(9), 1412–1415 (2006).
   PubMed Web of Science ®Google Scholar
• Koizumi W , KimYH, FujiiMet al. Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J. Cancer Res. Clin. Oncol.140(2), 319–328 (2014).
   PubMed Web of Science ®Google Scholar
• Kurokawa Y , MatsuyamaJ, NishikawaKet al. Docetaxel plus S-1 versus cisplatin plus S-1 in unresectable gastric cancer without measurable lesions: a randomized phase II trial (HERBIS-3). Gastric Cancer24(2), 428–434 (2021).
   PubMed Web of Science ®Google Scholar
• Al-Batran S-E , HomannN, PauligkCet al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet393(10184), 1948–1957 (2019).
   PubMed Web of Science ®Google Scholar
• Kang Y-K , YookJH, ParkY-Ket al. PRODIGY: A phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer. J. Clin. Oncol.39(26), 2903–2913 (2021).
   PubMed Web of Science ®Google Scholar
• Kang Y-K , YookJH, ParkY-Ket al. presNeoadjuvant docetaxel, oxaliplatin, and s-1 plus surgery and adjuvant s-1 for resectable advanced gastric cancer: final survival outcomes of the randomized phase 3 PRODIGY trial. J. Clin. Oncol.41(Suppl. 16), Abstract 4067 (2023).
   Web of Science ®Google Scholar
• Japanese Gastric Cancer Association Gastric Cancer . Japanese classification of gastric carcinoma: 3rd English edition. 14(2), 101–12 (2011).
   Google Scholar
• Becker K , LangerR, ReimDet al. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann. Surg.253(5), 934–939 (2011).
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA , TherasseP, BogaertsJet al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer45(2), 228–247 (2009).
   PubMed Web of Science ®Google Scholar
• US National Cancer Institute . Common Terminology Criteria for Adverse Events (CTCAE) (2017). https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf
   Google Scholar
• Katayama H , KurokawaY, NakamuraKet al. Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria. Surg. Today46(6), 668–685 (2016).
   PubMed Web of Science ®Google Scholar
• Simon R , WittesRE, EllenbergSS. Randomized phase II clinical trials. Cancer Treat. Rep.69(12), 1375–1381 (1985).
   PubMedGoogle Scholar
• Simon R . Optimal two-stage designs for phase II clinical trials. Control. Clin. Trials10(1), 1–10 (1989).
   PubMedGoogle Scholar
• Nakamura K , KuwataT, ShimodaTet al. Determination of the optimal cutoff percentage of residual tumors to define the pathological response rate for gastric cancer treated with preoperative therapy (JCOG1004-A). Gastric Cancer18(3), 597–604 (2015).
   PubMed Web of Science ®Google Scholar
• Janjigian YY , Van CutsemE, MuroKet al. MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer. Future Oncol.18(20), 2465–2473 (2022).
   PubMed Web of Science ®Google Scholar
• Bang YJ , CutsemEV, FuchsCSet al. KEYNOTE-585: phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. Future Oncol.15(9), 943–952 (2019).
   PubMed Web of Science ®Google Scholar
• Shitara K , LordickF, BangY-Jet al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet401(10389), 1655–1668 (2023).
   PubMed Web of Science ®Google Scholar
• Wainberg ZA , EnzingerPC, KangY-Ket al. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol.23(11), 1430–1440 (2022).
   PubMed Web of Science ®Google Scholar